




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification n 4 : C07K 15/04, 15/12, C07H 21/04 C12N 1/20, 15/00, C12P 19/34 C12P 21/00, 21/02, A61K 39/385</p>	<p>A1</p>	<p>(11) International Publication Number: WO 87/ 06590 (43) International Publication Date: 5 November 1987 (05.11.87)</p>
<p>(21) International Application Number: PCT/AU87/00107 (22) International Filing Date: 16 April 1987 (16.04.87) (31) Priority Application Numbers: PH 5559 PI 0846 (32) Priority Dates: 21 April 1986 (21.04.86) 13 March 1987 (13.03.87) (33) Priority Country: AU (71) Applicant (for all designated States except US): BIOENTERPRISES PTY. LTD. [AU/AU]; 28 Barcoo Street, East Roseville, NSW 2069 (AU). (72) Inventors; and (75) Inventors/Applicants (for US only) : BARNES, Thomas, Michael [AU/AU]; 20 Mooney Street, Lane Cove, NSW 2066 (AU). LEHRBACH, Philip, Ralph [AU/AU]; 5 Fiona Avenue, Wahroonga, NSW 2076 (AU). RUSSELL-JONES, Gregory, John [AU/AU]; 23 Greenfield Avenue, Middle Cove, NSW 2068 (AU).</p>		<p>(74) Agent: SPRUSON & FERGUSON; G.P.O. Box 3898, Sydney, NSW 2061 (AU). (81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FL, FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent), US. Published With international search report. With amended claims.</p>

(54) Title: IMMUNOPOTENTIATION



(57) Abstract

A class of carrier molecules which when linked to an immunogen can enhance the host's immune response to that immunogen regardless of whether the complex of carrier and immunogen is administered parenterally, enterally or orally to the host. The invention also provides processes for production of complexes according to the invention, as well as hybrid DNA sequences encoding complexes according to the invention, recombinant DNA molecules bearing said hybrid DNA sequences, transformant hosts and vaccines comprising complexes of the invention as well as methods for production of said vaccines.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

- 1 -

IMMUNOPOTENTIATIONTECHNICAL FIELD

The invention relates to a class of molecules which when linked to an immunogen can enhance the host's immune response to that immunogen regardless of whether the complex is administered parenterally, enterally or orally.

DEPOSITION OF STRAINS

Reference to ATCC 67331, is to an E. coli strain deposited with the American Type Culture Collection at 12301 Parklawn Drive, Rockville, MD 20852, USA on 2 March 1987.

BACKGROUND ART

In order to protect an animal against an invading pathogen (bacterial, viral or parasite) it is often advisable to vaccinate the animal with the whole organism or with such subunits of the pathogen as to elicit a protective immune response in the host. The immune response generated to such antigenic challenge can often be augmented by the co-administration of an immunopotentiating agent or adjuvant. The best of these agents are the depot type adjuvants (such as Freund's complete adjuvant, Freund's incomplete adjuvant and montanide). These adjuvants are capable of increasing the antibody response after antigen injection to some 50 to 100 times the level obtained with antigen injected alone.

Whilst adjuvants such as Freund's complete adjuvant, Freund's incomplete adjuvant and Montanide can greatly enhance the immune response to an antigen, they suffer from some disadvantages. When used with an antigen in an injectable form, large lesions often form at the site of injection, a situation which renders them unsatisfactory for such use in humans, pets or in meat animals. Furthermore, these adjuvants fail to act as immunopotentiating agents when administered orally or enterally.

DESCRIPTION OF THE INVENTION

This invention relates to a class of molecules which when linked chemically or genetically to an immunogen or hapten can enhance the host's immune response to the immunogen or hapten regardless of whether the complex is administered parenterally, enterally or orally. In addition their use does not result in the formation of large lesions at injection sites.

Molecules which have this activity can be defined as having the general property of being membrane proteins and the examples described herein are from specific types of membrane proteins, more specifically the outer membrane proteins of Gram negative bacteria. Examples cited

- 2 -

specifically include the TraT protein, an outer membrane protein of certain strains of E. coli which is responsible for the resistance of these strains to killing by serum. Other proteins of this class are the E. coli outer membrane proteins OmpA and OmpF. When quantities of TraT, OmpA or OmpF (hereafter called carrier) are injected intramuscularly into mice, without adjuvant, an antibody response is elicited which is comparable to that elicited when a soluble protein such as BSA, flagellin or sheep IgG is mixed with Freund's incomplete adjuvant and then injected. In fact, the antibody response elicited by these outer membrane proteins is so high as to be only marginally increased by adjuvation with Freund's incomplete adjuvant.

It has also been found that oral administration of TraT or OmpA results in the stimulation of significant titres of anti-TraT (1/4096) or anti-OmpA (1/892) serum antibodies.

Similarly it has been found that feeding of moderate quantities (10^9 - 10^{10}) of Salmonella or E. coli containing TraT in the outer membrane also enhances production of anti-TraT antibodies.

Covalent coupling of a hapten (Dinitrophenol, DNP), peptide (CSP) or a protein (Bovine Serum Albumin, BSA) to OmpA or TraT also acts to enhance the immune response to the DNP, CSP or BSA.

In a first embodiment the invention provides a complex comprising an immunogen coupled to a carrier molecule, such that the carrier molecule causes the immune response of a host to the immunogen to be enhanced when the complex is administered to said host, regardless of whether the complex is administered parenterally, enterally or orally, wherein said immunogen comprises either an antigen or a hapten and said carrier molecule comprises an integral membrane protein of prokaryote or eukaryote origin.

In a preferred embodiment the carrier molecule is an outer membrane protein of a Gram negative bacterium.

Preferably said Gram negative bacterium is E. coli or a Salmonella species.

More preferably the carrier molecule is the TraT protein or the outer membrane protein OmpA or OmpF, produced by strains of E. coli.

Preferred immunogens of the invention include CSP, the viral capsid protein VP7 from a rotavirus strain, and all or part of the eukaryotic protein minactivin.

The immunogen-carrier complex may be formed by chemical means including: conjugation, for instance, by using either a suitable conjugating or linking agent; and modification and/or reaction of

- 3 -

functional groups present on carrier and/or immunogen.

Thus, the invention provides a process for the production of a complex comprising, an immunogen coupled to a carrier molecule, said carrier molecule being an integral membrane protein (imp), of prokaryote or eukaryote origin and said immunogen comprising either an antigen or a hapten, wherein the carrier molecule causes the immune response of a host to the immunogen to be enhanced when the complex is administered to said host, regardless of whether the complex is administered parenterally, enterally or orally, which process comprises one or more of the following steps:

- a) reacting the immunogen with the carrier to form said complex;
- b) chemically modifying the immunogen to provide at least one functional group capable of forming a chemical linkage, and reacting the modified immunogen and carrier to form said complex;
- c) chemically modifying the carrier to provide at least one functional group capable of forming a chemical linkage and reacting the immunogen and modified carrier to form said complex;
- d) chemically modifying the immunogen and the carrier to provide functional groups capable of forming a chemical linkage, and reacting the modified immunogen and modified carrier to form said complex;
- e) reacting the immunogen with at least one linking agent and reacting the linked immunogen and the carrier molecule to form said complex;
- f) reacting the carrier with at least one linking agent and reacting the immunogen and linked carrier to form said complex;
- g) reacting the immunogen and carrier with at least one linking agent and reacting the linked immunogen and linked carrier to form said complex.

A preferred process of the invention comprises:

- (i) chemically modifying an immunogen to provide at least one functional group capable of forming a chemical linkage; and
- (ii) reacting the modified immunogen and the carrier to form said complex.

The linking agent may contain a disulfide bond or be cleavable by acid, base or periodate. Examples of such linking agents include N-(4-azidophenylthio)phthalimide, 4,4'-dithiobisphenylazide, dithiobis-(succinimidylpropionate), dimethyl-3,3'-dithiobispropionimidate.2HCl, 3,3'-dithiobis-(sulfosuccinimidylpropionate), ethyl-4-azidophenyl-1,4-dithiobutyrimidate.HCl, N-succinimidyl-(4-azidophenyl)-1,3'-dithio-

- 4 -

propionate, sulfosuccinimidyl-2-(m-azido-o-nitrobenzamido)-ethyl-1,3'-dithiopropionate, sulfosuccinimidyl-2-(p-azidosalicylamido)-ethyl-1,3'-dithiopropionate, N-succinimidyl-3-(2-pyridyldithio)propionate, sulfosuccinimidyl-(4-azidophenyldithio)-propionate, and 2-iminothiolane. Preferred cross-linking agents are disuccinimidyl tartrate and bis-[2-(succinimidylloxycarbonyloxy)-ethyl]sulfone.

Suitably, linking of the carrier and immunogen may be achieved by coupling the carrier to suitable groups of the immunogen.

Where the immunogen-carrier complex is formed by chemical conjugation, for instance, by using either a suitable conjugating or linking agent, preferred conjugating or linking agents include 1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide, glutaraldehyde, m-Maleimido benzoic acid n-hydroxysuccinimide ester, or N, N₁ Dicyclohexyl carbodiimide.

The linkage between the immunogen and the carrier molecule may also be made by the preparation of a hybrid protein molecule, such as is produced by recombinant DNA techniques by the insertion into, or addition to, the DNA sequence coding for the carrier, of DNA coding for the immunogen.

Hence, the invention provides a process for the preparation of said complex of carrier molecule with immunogen, which process comprises preparing a hybrid protein molecule. In a preferred process the hybrid protein molecule is produced by recombinant DNA techniques, by the insertion into, or the addition to, the DNA sequence coding for the carrier, of DNA coding for the immunogen.

The invention also provides a hybrid DNA sequence which consists of: a first DNA sequence comprising a DNA sequence which acts as a coding sequence for at least part of an integral membrane protein of prokaryote or eukaryote origin fused to a DNA sequence coding for the amino acid sequence of an immunogen; or a second DNA sequence which hybridizes to said first DNA sequence, from whatever source obtained, including natural, synthetic and semi-synthetic sources; a DNA sequence related by mutation, including single or multiple base substitutions, deletions, insertions and inversions to said first DNA sequence; or a DNA sequence comprising sequences of codons which, on expression, code for a polypeptide displaying similar immunological or biological activity to a polypeptide coded for on expression of the codons of any of the foregoing hybrid DNA sequences and inserts.

Preferred hybrid DNA sequences of the invention code for at least

- 5 -

part of TraT, OmpF or OmpA, linked to a DNA sequence coding for the amino acid sequence of an immunogen such that the resulting TraT-(OmpF or OmpA) hybrid proteins are exported to and exposed on the host cell surface.

The invention also provides a fused gene comprising a hybrid DNA sequence of the invention fused to a portable promoter. A preferred promoter according to the invention, is the P_L promoter of the bacteriophage lambda.

Further, the invention provides, a recombinant DNA molecule which comprises a hybrid DNA sequence according to the invention and vector DNA, wherein the vector DNA is plasmid, bacteriophage, viral or cosmid DNA.

A preferred recombinant DNA molecule of the invention includes an expression control sequence operatively linked to the hybrid DNA sequence.

Particularly preferred recombinant DNA molecules according to the invention include: pBTA371, pBTA439, pBTA449, pBTA450 and pBTA586.

Within the scope of the invention is a process for the manufacture of a recombinant DNA molecule which process comprises:

introducing into a cloning vehicle, a hybrid DNA sequence according to the invention.

Preferably the process also includes the step of introducing an expression control sequence into the cloning vehicle.

The invention also provides a host transformed with at least one recombinant DNA molecule according to the invention.

Suitable hosts include E. coli and Salmonella sp.

A preferred transformant is ATCC 67331 (also designated CCTCC 87026).

Also included within the scope of the invention is a process for transforming a host, which process comprises the step of: introducing into a host a recombinant DNA molecule according to the invention.

In a further embodiment the invention provides the complex of carrier with immunogen adapted for parenteral injection into a host or adapted for oral or enteral administration, to elicit both a humoral and mucosal antibody response.

Included within the scope of the invention is a process for the preparation of the complex of carrier with immunogen in a form adapted for parenteral, enteral or oral administration to a host which process comprises preparing the complex and adding it to a pharmaceutically acceptable diluent.

Preferably the invention provides a whole bacterial cell vaccine comprising a hybrid protein according to the invention is exposed on the bacterial cell surface for presentation to the immune system. The

- 6 -

whole cell vaccine may be a live or killed whole cell oral vaccine. Alternatively the hybrid protein can be purified from the cell membrane or cellular contents and used as a subunit vaccine administered parenterally, enterally or orally.

The invention also provides a process for the manufacture of a microorganism with the genetic information for the biosynthesis of a hybrid protein comprising at least an immunogen and a carrier comprising at least part of an imp of prokaryote or eukaryote origin, such that the resulting hybrid peptide is exposed on the host cell surface which process comprises culturing a microorganism carrying the necessary genetic information. Where the microorganism is used to provide a subunit vaccine, the process additionally comprises purifying the hybrid peptide from the cell membrane or cellular contents.

BRIEF DESCRIPTION OF THE DRAWINGS

- Figure 1 Modifications of the immune response by adjuvants. Rabbits were injected i.m. with TraT, (Fig.1a) and BSA (Fig.1b) alone or in combination with various adjuvants. TraT and BSA were mixed with F.I.A. (Δ - Δ); Montanide 888 (\bullet - \bullet), Alhydrogel (\square - \square); saline (x-x) Figs. 1a + 1b. A comparison of the antibody response generated to TraT (x-x) OmpA (\blacksquare - \blacksquare) and OmpF (o-o) injected in saline is presented in Fig. 1c.
- Figure 2 Stimulation of the antibody response to DNP and BSA by coupling to TraT and OmpA. Dinitrophenylated preparations of TraT (+-----+), Omp A (X-----X) and BSA (∇ ----- ∇) were compared for their ability to stimulate anti-carrier (Fig. 2a) and anti-DNP antibody responses (Fig. 2b) following im injection. The antibody response to TraT (\bullet ----- \bullet) and Omp A (\blacksquare ----- \blacksquare) injected alone was also determined. Similarly BSA was injected in saline (O-----O), mixed in FIA (∇ ----- ∇) or covalently conjugated to TraT (∇ ----- ∇) or Omp A (\square ----- \square) and the anti-BSA response was determined (Fig. 2c). The anti-TraT and anti-Omp A responses to these conjugates are shown in Fig. 2a. The immunopotentiating activity of imps was examined when BSA was injected covalently linked to TraT (∇ ----- ∇) or Omp A (\square ----- \square), when it was mixed with TraT (Δ ----- Δ) or Omp A (\blacksquare ----- \blacksquare) or when it was injected at a separate site from TraT (Δ ----- Δ) or Omp A (\bullet ----- \bullet) (Fig. 2d).

- 7 -

Figure 3a shows the construction of the plasmids and pBTA449, pBTA439 and pBTA371.

Figure 3b shows an SDS-PAGE and Western for expression of TraT and the TraT-VP7 fusion protein.

Figure 3c shows an autoradiograph of cell surface labelled E.coli expressing TraT (Lane 1), TraT-VP7 (Lane 3) and control (Lane 2). Cells were labelled with ^{125}I and lactoperoxidase.

Figure 4a shows the construction of the plasmids pBTA450 and pBTA586.

Figure 4b shows the SDS polyacrylamide gel of a TraT minactivin hybrid protein (TraTMIN) expressed from pBTA586

Abbreviations (Fig. 3 and 4): Resistance to; ampicillin, Ap^r ; chloramphenicol, Cm^r ; mercuric chloride, Hg^+ ; tetracycline, Tc ; VP7 structural gene, VP7; TraT structural gene, TraT; TraT VP7 gene fusion, TraT-VP7; lambda bacteriophage P_L promoter region, P_L . Restriction endonucleases, A, AluI; A, AvaI; D, DraI B, BamHI; E, EcoRI; N, NdeI; Pv, PvuII; RV, EcoRV; Ss SspI.

BEST MODE OF CARRYING OUT THE INVENTION

The following examples illustrate preferred embodiments of the present invention, and are in no way limiting on the scope of the invention.

EXAMPLE 1

Isolation of TraT, OmpA and OmpF

E.coli (Strain BTA 1352 containing the plasmid pBTA439) were grown in a fermenter at 30°C in MEB medium. Cells were harvested following 2 hours of heat induction of TraT at 42°C. Bacteria were concentrated to 2 litres using a 0.1 μ hollow fibre cartridge in a Amicon DCIOLA concentrator. The cells were then washed with 10 litres of distilled water and reconcentrated to 800ml. The bacterial slurry was then removed from the concentrate and the outer membrane proteins (TraT, OmpA and OmpF) extracted from the cells by the addition of 200ml of 1M sodium acetate buffer pH 2.5, followed by 1 litre of 10% cetrinide (Sigma) in 40% ETOH plus 1M CaCl_2 . The extraction was allowed to proceed overnight at room temperature, (RT) after which the bacteria were removed by centrifugation (17,000 xg, 20 min).

TraT and OmpF were precipitated from the supernatant by the addition of ethanol to 50% and centrifugation (40000 xg, 10 min). OmpA was then precipitated from the final supernatant by addition of ethanol to 80%.

Ion Exchange Chromatography

The 50% ethanol pellet containing OmpF and TraT was resuspended in 20mM Na acetate buffer pH5.0 containing 0.5% Zwittergent, and loaded onto a 5x50cm column of DEAE Sepharose (Pharmacia Fine Chemicals) previously

- 8 -

equilibrated with 20mM Na Acetate buffer pH5.0 containing 0.1% Zwittergent. TraT was found in the column flow through, and bound OmpF was eluted from the column using a linear gradient of 0-1.0M NaCl in equilibration buffer. Fractions were analysed by SDS-PAGE using a modification of the method of Laemmli (Laemmli, U.K. NATURE (LOND) 227:680 1970; Salit et al., J.Exp. Med. 151:716. 1980) and fractions containing isolated TraT or OmpF were pooled and concentrated by ethanol precipitation. Sephacryl S-300 chromatography

The 80% ethanol pellet containing OmpA was resuspended in 1% SDS in 20 mM Tris. HCl. pH 8.8. Fractions were collected, analysed by SDS-PAGE and fractions containing OmpA were pooled and concentrated by ethanol precipitation.

Proteins purified by the above methods were found to be free of LPS when examined by SDS-PAGE and silver stained by the method of Tsai C.M. and Frasch, C.E. Anal. Biochem 119:115. (1982).

Dinitrophenylation of Carriers

TraT, OmpA and OmpF were dinitrophenylated according to the method of Little and Eisen "Methods in Immunology and Immunochemistry" (E.D. Williams, CA and Chase, M.W.) 1, p.128 Academic Press, N.Y. (1967). Briefly, carriers (in 0.1M carb/bicarb buffer pH9.5) were reacted with a 0.1M solution of DNFB (in Acetone) overnight at RT. The proteins were then dialysed extensively against the coupling buffer.

Glutaraldehyde coupling

Bovine serum albumin (BSA) (from Sigma Chemical Co. St. Louis, Miss.) was coupled to TraT, OmpA and OmpF using the two step glutaraldehyde procedure of Avrameus et al (1978). Briefly, BSA was reacted with 0.2% glutaraldehyde for 2 hrs at R.T. The protein was then dialysed overnight against carb/bicarb buffer pH 9.5 followed by the addition of omp's at a molar ratio's of 1:1 BSA:omp and reacted for 24 hrs at RT. Finally ethanolamine (Sigma) was added to a final concentration of 0.1M, (1 hr, RT) followed by overnight dialysis at 4C against 0.1M carb/bicarb buffer pH 9.5.

ANTIGEN ADMINISTRATION

1. Rabbits

New Zealand white rabbits (2-2.5kg) were injected intramuscularly with antigen in 0.5ml of sterile physiological saline.

Injections were performed on days 0 and 36. Weekly bleedings were obtained from the longitudinal vein in the rabbits ear and antibody titres were measured by a standard ELISA using TraT, OmpA, BSA or DNP-sheep IgG as coating antigens.

2. Mice

Female C57BL/6J mice (18-22gm) were obtained from the Animal Resources Centre (Perth, Western Australia). All mice were starved for 3-4 hours prior to oral or intramuscular (i.m.) administration of antigens. Mice were fed antigen at appropriate concentrations in 0.5ml of 0.1M carb/bicarbonate buffer pH9.5 using a specially prepared feeding needle. Parallel doses of antigen were injected i.m., in 0.1ml of sterile physiological saline, into the left hind leg. Groups of 5 mice receiving antigen either orally or im were given two identical doses of antigen, on day 0 and day 14. A blood sample was taken (approx. 0.5ml) from the retro-orbital plexus on day 14 and day 21. Mice were then sacrificed by cervical dislocation and gut washes performed on the small intestine in the following manner. The small intestine was carefully removed and a small quantity of washing buffer (1.0ml, 30 mM Tris.HCl pH8.8, 0.9% NaCl, 50 mM EDTA plus 1.0% Tween 20) introduced into the lumen of the gut via a blunt ended feeding needle. After gently kneading the intestine and contents were squeezed out through forefinger and thumb. Gut washes so obtained were immediately centrifuged to remove debris and stored at -20°C until assayed. Blood samples were allowed to clot at 4°C before removal of the serum and storage at -20°C.

Enzyme Linked Immunosorbent Assay (ELISA)

The ELISA for the determination of antibody titres was performed as described previously by Russell-Jones et al. J. Exp. Med 160:1467,(1984). Titres are expressed as the reciprocal of the antiserum dilution, which gave a ELISA reading of 0.5 after 45 mins at 37°C.

EXAMPLE 2

Effect of adjuvant on the antibody response to integral membrane proteins

The potential of imps to act as self adjuvanting molecules when injected i.m. was examined. The antibody titre generated when TraT Fig (1a, x - x) or BSA Fig (1b x - x) were injected alone was compared to that generated when TraT (Fig 1a) or BSA (Fig 1b) were mixed with a number of adjuvants.

Intramuscular administration of TraT, in saline quickly elicited high titres of serum antibody to the immunizing agent (Fig 1a). In fact the titres generated by TraT in saline could only be increased by a factor of 4-8 fold by injection of this antigen in adjuvants such as montanide or FIA (Fig. 1a). This is in direct contrast to the response generated by the soluble antigen BSA. In this case a poor antibody response was generated to the antigens administered in saline, but was markedly

- 10 -

increased 60-100 fold by injection of the antigen in FIA or montanide (Fig. 1b).

Similarly injection of OmpA and OmpF in saline alone also elicited high serum Ab titres. In fact, surprisingly similar antibody titres were elicited by injection of 100µg TraT, OmpA or OmpF (Fig 1c).

EXAMPLE 3

Examination of the adjuvanting ability of immunogen - imp complexes

TraT and OmpA were examined for their ability to augment anti-hapten (DNP) and anti-protein (BSA) responses. The twoimps were substituted with DNP using dinitrofluorobenzene (see Example 1) or were glutaraldehyde cross-linked to BSA (see Example 1) and then injected i.m.

Coupling of DNP or BSA to either TraT or OmpA had little effect on the generation of an anti-imp response (Fig. 2a, cf 1c). Dinitrophenylation of theimps did however increase the anti-DNP response some four to sixteen fold higher than the response seen to DNP-BSA when it was injected in saline (Fig. 2b). Similarly the anti-BSA response was greatly enhanced when BSA was administered in FIA (fig. 2c). The immunopotentiating effect of TraT or OmpA on the anti-BSA response was greatest when BSA was covalently linked to theimps. In fact injection of BSA at a separate site from the imp actually depressed the secondary response to BSA (cf 2d and 2c).

EXAMPLE 4

Effect of Dose on the immune response to TraT

The effect of increasing dose of TraT administered either i.m. or per os. was examined in mice.

Groups of 5 mice were immunized by intramuscular injection or oral feeding with increasing doses of TraT. Mice received doses on day 0 and day 14. On day 21 mice were bled, sacrificed and gut washes obtained. Antibody titres were increased by ELISA.

As can be seen from Table 1 increasing doses of TraT administered orally or parenterally led to a dose dependent increase in serum anti-TraT Ab response.

Parenteral administration was however much more effective than oral administration.

TABLE 1

Dose of antigen	Route of administration							
	intramuscular		per os					
	serum	IgG	serum	IgG	Gut	IgA	Gut	IgA
0.1	2,048 ±	900	-	-	6 ±	2	7 ±	4
1	3,565 ±	1,300	7 ±	2.6	9 ±	3	6 ±	2
2	10,809 ±	1,900	2 ±	2	13 ±	5	56 ±	8
5	5,405 ±	400	13.9 ±	9	24 ±	3	42 ±	7
10	28,526 ±	7,280	12.0 ±	2	16 ±	4	18 ±	5
25	24,833 ±	6,040	9.1 ±	3	6 ±	2	7 ±	4
50	49,667 ±	13,020	97 ±	25	9 ±	5	11 ±	6
100	65,536 ±	16,000	64 ±	36	-		-	
200	150,562 ±	64,000	675 ±	400	32 ±	20	14 ±	7
400	86,475 ±	19,000	97 ±	45	6 ±	2	24 ±	13

EXAMPLE 5Examination of the hapten density on the ability of the imps to act as carriers for an anti-DNP response

TraT, OmpA and OmpF were substituted with different ratios of DNP:imp as described in Example 1. Groups of 5 mice were injected i.m with 50µg doses of the DNP : carrier complex on days 0 and 14. On day 21 mice were bled and the Ab titres determined by ELISA.

Increasing the substitution ratio of DNP to carrier from 0.5 : 1 to 4 : 1 increased the anti-hapten response considerably. Substitutions of greater than 10 : 1 appeared to decrease the anti-hapten response.

- 12 -

TABLE 2

Antigen	Substitution	Route	Antibody response (serum IgG)		
DNP TraT	0.5 : 1	i.m	21	±	13
	1 : 1	i.m	337	±	71
	2 : 1	i.m	1552	±	536
	4 : 1	i.m	3104	±	954
DNP-ompA	0.5 : 1	i.m	-		-
	1 : 1	i.m	84	±	20
	2 : 1	i.m	256	±	109
	4 : 1	i.m	776	±	164
DNP - omp F	0.5 : 1	i.m	7	±	4
	1 : 1	i.m	49	±	12
	2 : 1	i.m	97	±	28
	4 : 1	i.m	337	±	115

EXAMPLE 6Generation of an anti-CSP response by coupling to TraT

A synthetic peptide derived from the circumsporozoite protein (CSP) antigen of *P. falciparum* of the following sequence: NH₂ Cys (Asn Pro Asn Ala)₄, was synthesized and used to conjugate to TraT in order to examine the adjuvating effect of TraT for the peptide antigen.

The CSP antigen was coupled to Tra T using either glutaraldehyde or maleimidobenzoic acid n-hydroxy succinimide ester (MBS). Conjugates prepared in this way were injected into a) rabbits on day 0, day 28, which were then bled on day 38, or b) groups of 5 mice on day 0 and 14. Mice were then bled on day 21. Antibody titres were determined as described previously.

Immunization of rabbits or mice with the CSP antigen coupled to TraT using either glutaraldehyde or MBS, resulted in the stimulation of an anti-CSP response which was comparable to that seen when the antigen was coupled to BSA and injected in montanide.

TABLE 3

Antigen (serum)	Coupling procedure	Animal	Dose (μ g)	Antibody anti TraT	Response anti CSP
CSP-TraT	glutaraldehyde	rabbit	200	28,526	147
CSP-TraT	MBS	rabbit	200	12,417	1,024
CSP + montanide	---	rabbit	200	28	-
CSP-BSA+montanide	glutaraldehyde	rabbit	200	---	2,353
CSP-TraT	glutaraldehyde	mouse	50	228,209	32
CSP - TraT	MBS	mouse	50	3,566	128
CSP + montanide	---	mouse	50	---	---
CSP-BSA + montanide	glutaraldehyde	mouse	50	---	9

EXAMPLE 7Genetic construction of a TraT-immunogen protein complex.

The gene coding for the TraT protein is located on the R plasmid R100 (or R6-5) and the nucleotide sequence of this gene has been determined (Ogata et al, J. Bacteriol 151: 819-827). TraT is an oligomeric lipoprotein situated in the outer membrane which is simultaneously exposed at the cell surface and associated with peptidoglycan, an internal structure. Using these facts a plasmid vector was constructed (Fig. 3a) by initially cloning a 6.0 kb EcoRI fragment of the R100 plasmid which contains TraT into the multicopy plasmid pBR329. Further deletion of an unwanted 3 kb BamHI fragment and inactivation, by insertion of a small blunted ended HaeIII fragment of M13mp8, in an EcoRV site produced pBTA449. This vector plasmid contains the natural TraT promoter which directs the synthesis of TraT. The expression of TraT (or TraT-hybrid proteins subsequently constructed) can be boosted by the replacement of the weak TraT natural promoter with the strong lambda bacteriophage P_L promoter (e.g. in plasmid pBTA439 Fig. 3a or pBTA586 Fig. 4a). The TraT gene contains an EcoRV site (unique to pBTA449) where foreign DNA sequences may be inserted such that fusions between TraT and the encoded foreign protein are exported correctly to the cell surface and result in exposure of the foreign protein segment at the cell surface.

In one example the gene for a viral capsid protein (VP7) was used to form TraT-VP7 hybrid proteins. VP7 is a structural protein of rotavirus and antibodies raised against purified VP7 protein effectively neutralize viral infectivity in cell culture (Dyall-Smith *et al* 1985 *In Infectious Diarrhoea in the young ed. S.Tzipori*). Thus the VP7 protein, in an appropriately expressed form, is a prime candidate for inclusion in a

- 14 -

rotavirus vaccine.

An AluI PvuII restriction fragment of the rotavirus NCDV VP7 gene was cloned into the EcoRV site of plasmid pBTA449 and subsequently overexpressed with the P_L promoter (pBTA371, Fig. 3a). For expression the plasmid pBTA371 was used to transform E.coli K-12 strain N4830 (Joyce et al, PNAS 80, 1830-1834 1983) which contains the thermolabile cI repressor of Lambda. Cells transformed with pBTA371 were grown overnight in MEB medium (Mott et al PNAS 82, 88-92 1985) with 100ug/ml ampicillin at 30°C. Cells were diluted in MEB medium, grown at 30°C to an OD₆₀₀ of 1.0 when prewarmed (65°) MEB medium was added in equal volume to equilibrate the temperature to 42°C. Following 4 hours of growth at 42°C the cells were harvested and examined for induction of the TraT-VP7 hybrid protein. In E.coli N4830 high level expression of the TraT-VP7 protein complex (10-15% total cell protein or greater than 500,000 copies per cell) was observed. A significant proportion of this complex was present in the outer membrane fraction (Fig. 3b, 3c).

In another example a method of producing a protein that is a hybrid of part of the TraT protein coding sequence and all or part of a eukaryotic protein coding sequence, minactivin, follows.

As shown in Fig. 4a the plasmid pBTA440 was digested with SspI and DraI and a 1110bp fragment was isolated from an agarose gel. This fragment was ligated to the vector pBTA449 digested with EcoRV creating pBTA450. pBTA450 was then digested with AvaI and a purified 2800 bp fragment ligated to the plasmid pLK57 digested with AvaI to create plasmid pBTA586. This places part of the minactivin coding sequence under the control of the lambda P_L promoter and fused to the coding sequence of the first 80 amino acids of TraT gene, the first 20 of which constitutes a signal sequence that results in the hybrid appearing in the outer membrane of E.coli. This signal sequence is cleaved off during transport to the outer membrane, which is the normal location of the TraT protein.

When plasmid pBTA586 is transformed into an appropriate host, such as N4830, and induced with temperature shift as described above, the TraT-minactivin hybrid protein appears in the outer membrane fraction, as shown in Figure 4b.

EXAMPLE 8

Oral feeding of strains expressing TraT in the outer membrane

Female C57B1/65 mice (20-25 g) were fed 10^9 - 10^{10} bacteria (E. coli or a galE⁻ mutant of S. typhimurium) expressing TraT in their outer membranes. Controls received the same strains without the TraT protein.

- 15 -

After 1 week mice were bled and the anti-TraT titres measured as outlined previously.

Results are expressed in Table 4 as reciprocal antibody titre and represent the average of 10 mice.

TABLE 4Antibody Response to Orally Administered Whole Bacteria

<u>Strain</u>	<u>TraT</u>	<u>Anti TraT</u>		<u>Anti OmpA</u>	
		<u>Serum</u>	<u>Intestine</u>	<u>Serum</u>	<u>Intestine</u>
<u>E. coli</u>	-	3	5.2	14	2
	+	350	15	110	2
<u>Salmonella</u>	-	12	2	ND	ND
	+	650	6	ND	ND

INDUSTRIAL APPLICATION

The current invention is of use in the preparation of vaccines for use in humans, pets and meat animals, and in general for potentiating the response to an antigen on oral, enteral or parenteral administration.

- 16 -

CLAIMS

1. A complex comprising an immunogen coupled to a carrier molecule, such that the carrier molecule causes the immune response of a host to the immunogen to be enhanced when the complex is administered to said host, regardless of whether the complex is administered parenterally, enterally or orally, wherein said immunogen comprises either an antigen or a hapten and said carrier molecule comprises an integral membrane protein of prokaryote or eukaryote origin.

2. A complex according to claim 1 wherein said carrier molecule is an outer membrane protein of a Gram negative bacterium.

3. A complex according to claim 2 wherein said carrier molecule is a membrane protein of E. coli or a Salmonella species.

4. A complex according to claim 3 wherein said membrane protein is the TraT protein, or the outer membrane protein OmpA, or the outer membrane protein OmpF, produced by strains of E. coli.

5. A complex according to claim 4 wherein said membrane protein is the protein TraT.

6. A complex according to any one of claims 1 to 5, wherein the immunogen is CSP, the viral capsid protein VP7 from a rotavirus, or all or part of minactivin.

7. A complex according to any one of claim 1 to 6 wherein coupling of carrier to immunogen is by chemical means.

8. A complex according to claim 7 wherein said coupling is by chemical conjugation comprising use of either a conjugating or linking agent.

9. A complex according to claim 8 wherein said conjugating or linking agent is 1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide, glutaraldehyde, m-Maleimido benzoic acid n-hydroxysuccinimide ester, or N, N₁ dicyclohexyl carbodiimide.

10. A complex according to claim 8 wherein said linking agent contains a disulfide bond or is cleavable by acid, base or periodate.

11. A complex according to claim 10 wherein the linking agent is selected from N-(4-azidophenylthio)phthalimide, 4,4'-dithiobisphenylazide, dithiobis-(succinimidylpropionate), dimethyl-3,3'-dithiobispropionimide. 2HCl, 3,3'-dithiobis-(sulfosuccinimidylpropionate), ethyl-4-azidophenyl-1, 4-dithiobutyrimidate, HCl, N-succinimidyl-(4-azidophenyl)-1,3'-dithiopropionate, sulfosuccinimidyl-2-(m-azido-o-nitrobenzamido)-ethyl-1,3'-dithiopropionate, sulfosuccinimidyl-2-(p-azidosalicylamido)-ethyl-1,3'-dithiopropionate, N-succinimidyl-3-(2-pyridyldithio)propionate,

- 17 -

sulfosuccinimidyl-(4-azidophenyldithio)-propionate, 2-iminothiolane-disuccinimidyl tartrate and bis-[2-(succinimidyloxycarbonyloxy)-ethyl]-sulfone.

12. A complex according to claim 11 wherein the linking agent is 2-iminothiolanedisuccinimidyl tartrate or bis-[2-(succinimidyloxy-carbonyloxy)-ethyl]sulfone.

13. A process for the preparation of a complex according to any one of claims 1 to 12 which process comprises coupling the carrier molecule to the immunogen by chemical means.

14. A process according to claim 13 wherein the process comprises one or more of the following steps:

- a) reacting the immunogen with the carrier to form said complex;
- b) chemically modifying the immunogen to provide at least one functional group capable of forming a chemical linkage, and reacting the modified immunogen and carrier to form said complex;
- c) chemically modifying the carrier to provide at least one functional group capable of forming a chemical linkage and reacting the immunogen and modified carrier to form said complex;
- d) chemically modifying the immunogen and the carrier to provide functional groups capable of forming a chemical linkage, and reacting the modified immunogen and modified carrier to form said complex;
- e) reacting the immunogen with at least one linking agent and reacting the linked immunogen and the carrier molecule to form said complex;
- f) reacting the carrier with at least one linking agent and reacting the immunogen and linked carrier to form said complex;
- g) reacting the immunogen and carrier with at least one linking agent and reacting the linked immunogen and linked carrier to form said complex.

15. A process according to claim 14 which process comprises:

- (i) chemically modifying an immunogen to provide at least one functional group capable of forming a chemical linkage; and
- (ii) reacting the modified immunogen and the carrier to form said complex.

16. A complex according to any one of claims 1 to 6 wherein said coupling is by means of genetic linkage.

17. A complex according to claim 16 wherein the complex comprises a hybrid protein molecule.

- 18 -

18. A process for the preparation of a complex according to claim 17, which process comprises preparing a hybrid protein molecule by recombinant DNA techniques.

19. A process according to claim 18 where the complex is produced by inserting into or adding to the DNA sequence coding for the carrier, DNA coding for the immunogen.

20. A hybrid DNA sequence which consists of: a first DNA sequence comprising a DNA sequence which acts as a coding sequence for at least part of an integral membrane protein of prokaryote or eukaryote origin fused to a DNA sequence coding for the amino acid sequence of an immunogen; or a second DNA sequence which hybridizes to said first DNA sequence, from whatever source obtained, including natural, synthetic and semi-synthetic sources; a DNA sequence related by mutation, including single or multiple base substitutions, deletions, insertions and inversions to said first DNA sequence; or a DNA sequence comprising sequences of codons which, on expression, code for a polypeptide displaying similar immunological or biological activity to a polypeptide coded for on expression of the codons of any of the foregoing hybrid DNA sequences and inserts.

21. A hybrid DNA sequence according to claim 20 wherein said hybrid DNA sequence codes for at least part of TraT, OmpF or OmpA linked to a DNA sequence coding for the amino acid sequence of an immunogen.

22. A hybrid DNA sequence according to claim 21 wherein said hybrid DNA sequence codes for at least part of TraT linked to a DNA sequence coding for the amino acid sequence of an immunogen.

23. A hybrid DNA sequence according to claim 21 or 22, said DNA sequence coding for a TraT, OmpF or OmpA hybrid protein capable of being exported to and exposed on the surface of a host cell.

24. A fused gene comprising a hybrid DNA sequence according to any one of claims 20 to 23 fused to a portable promoter.

25. A fused gene according to claim 24 wherein the promoter is the P_L promoter of the bacteriophage λ .

26. A recombinant DNA molecule comprising a hybrid DNA sequence or fused gene according to any one of claims 20 to 25 and vector DNA.

27. A recombinant DNA molecule according to claim 26 wherein the vector DNA is of plasmid, bacteriophage, viral or cosmid origin.

28. A recombinant DNA molecule according to claim 27 which comprises an expression control sequence operatively linked to the hybrid DNA sequence.

29. The recombinant DNA molecule pBTA371, pBTA439, pBTA449, pBTA450

or pBTA 586.

30. A process for the production of a recombinant DNA molecule according to any one of claims 26 to 29 which process comprises:

introducing into vector DNA, a hybrid DNA sequence or fused gene according to any one of claims 20 to 27.

31. A process according to claim 30 which process additionally comprises introducing an expression control sequence into the vector DNA.

32. A transformant host comprising a host cell transformed with at least one recombinant DNA molecule according to any one of claims 26 to 29.

33. A transformant host according to claim 32 wherein the host is E. coli or a Salmonella species.

34. ATCC 67331.

35. A process for the transformation of a host comprising:

introducing into a host a recombinant DNA molecule according to any one of claims 26 to 29.

36. A whole bacterial cell vaccine comprising a hybrid protein according to claim 16 exposed on the bacterial cell surface for presentation to the immune system.

37. A whole cell vaccine according to claim 36 which vaccine is a live or killed whole cell oral vaccine.

38. A vaccine comprising a hybrid protein according to claim 17 purified from the cell membrane or cellular contents.

39. A process for the manufacture of a microorganism with the genetic information for the biosynthesis of a hybrid protein comprising at least an immunogen and a carrier said carrier comprising at least part of an imp of prokaryote or eukaryote origin, such that the resulting hybrid protein is exposed on the host cell surface, which process comprises culturing a microorganism carrying the necessary genetic information.

40. A process for the production of a subunit vaccine which process comprises purifying a hybrid protein according to claim 17 from the cell membrane or cellular contents of a microorganism produced by a process according to claim 39.

41. A process for the preparation of a complex of carrier with immunogen in a form adapted for parenteral, oral, or enteral administration to a host which process comprises:

preparing the complex and adding it to a pharmaceutically acceptable diluent.

42. A complex according to any one of claims 1 to 6 adapted for parenteral, enteral or oral administration to a host.

1. A complex comprising an immunogen coupled to a carrier molecule, characterised in that said carrier molecule causes enhancement of the immune response of a host to said immunogen, such that said enhancement is not substantially increased by the addition of an adjuvant to said complex when said complex is administered to said host, regardless of whether said complex is administered parenterally, enterally or orally, wherein said immunogen comprises either an antigen or a hapten and said carrier molecule comprises an integral membrane protein of prokaryote or eukaryote origin.

2. A complex according to claim 1 wherein said carrier molecule is an outer membrane protein of a Gram negative bacterium.

3. A complex according to claim 2 wherein said carrier molecule is a membrane protein of E. coli or a Salmonella species.

4. A complex according to claim 3 wherein said membrane protein is the TraT protein, or the outer membrane protein OmpA, or the outer membrane protein OmpF, produced by strains of E. coli.

5. A complex according to claim 4 wherein said membrane protein is the protein TraT.

6. A complex according to any one of claims 1 to 5, wherein the immunogen is CSP, the viral capsid protein VP7 from a rotavirus, or all or part of minactivin.

7. A complex according to claim 6, wherein the immunogen is CSP.

8. A complex according to any one of claim 1 to 7 wherein coupling of carrier to immunogen is by chemical means.

9. A complex according to claim 8 wherein said coupling is by chemical conjugation comprising use of either a conjugating or linking agent.

10. A complex according to claim 9 wherein said conjugating or linking agent is 1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide, glutaraldehyde, m-Maleimido benzoic acid n-hydroxysuccinimide ester, or N, N₁ dicyclohexyl carbodiimide.

11. A complex according to claim 9 wherein said linking agent contains a disulfide bond or is cleavable by acid, base or periodate.

12. A complex according to claim 11 wherein the linking agent is selected from N-(4-azidophenylthio)phthalimide, 4,4'-dithiobisphenylazide, dithiobis-(succinimidylpropionate), dimethyl-3,3'-dithiobispropionimide. 2HCl, 3,3'-dithiobis-(sulfosuccinimidylpropionate), ethyl-4-azidophenyl-1, 4-dithiobutyrimidate, HCl, N-succinimidyl-(4-azidophenyl)-1,3'-dithio-propionate, sulfosuccinimidyl-2-(m-azido-o-nitrobenzamido)-ethyl-1,3'-

dithiopropionate, sulfosuccinimidyl-2-(p-azidosalicylamido)-ethyl-1,3'-dithiopropionate, N-succinimidyl-3-(2-pyridyldithio)propionate, sulfosuccinimidyl-(4-azidophenyldithio)-propionate, 2-iminothiolane-disuccinimidyl tartrate and bis-[2-(succinimidyloxycarbonyloxy)-ethyl]-sulfone.

13. A complex according to claim 12 wherein the linking agent is 2-iminothiolanedisuccinimidyl tartrate or bis-[2-(succinimidyloxycarbonyloxy)-ethyl]sulfone.

14. A process for the preparation of a complex according to any one of claims 1 to 13 which process comprises coupling the carrier molecule to the immunogen by chemical means.

15. A process according to claim 14 wherein the process comprises one or more of the following steps:

- a) reacting the immunogen with the carrier to form said complex;
- b) chemically modifying the immunogen to provide at least one functional group capable of forming a chemical linkage, and reacting the modified immunogen and carrier to form said complex;
- c) chemically modifying the carrier to provide at least one functional group capable of forming a chemical linkage and reacting the immunogen and modified carrier to form said complex;
- d) chemically modifying the immunogen and the carrier to provide functional groups capable of forming a chemical linkage, and reacting the modified immunogen and modified carrier to form said complex;
- e) reacting the immunogen with at least one linking agent and reacting the linked immunogen and the carrier molecule to form said complex;
- f) reacting the carrier with at least one linking agent and reacting the immunogen and linked carrier to form said complex;
- g) reacting the immunogen and carrier with at least one linking agent and reacting the linked immunogen and linked carrier to form said complex.

16. A process according to claim 15 which process comprises:

- (i) chemically modifying an immunogen to provide at least one functional group capable of forming a chemical linkage; and
- (ii) reacting the modified immunogen and the carrier to form said complex.

17. A complex according to any one of claims 1 to 7 wherein said coupling is by means of genetic linkage.

18. A complex according to claim 17 wherein the complex comprises a hybrid protein molecule.

19. A process for the preparation of a complex according to claim 18, which process comprises preparing a hybrid protein molecule by recombinant DNA techniques.

20. A process according to claim 19 where the complex is produced by inserting into or adding to the DNA sequence coding for the carrier, DNA coding for the immunogen.

21. A hybrid DNA sequence comprising: a first DNA sequence comprising a coding sequence for a complex comprising a carrier molecule comprising at least part of an integral membrane protein of prokaryote or eukaryote origin fused to an immunogen; or a second DNA sequence which hybridizes to said first DNA sequence, from whatever source obtained, including natural, synthetic and semi-synthetic sources; a DNA sequence related by mutation, including single or multiple base substitutions, deletions, insertions and inversions to said first DNA sequence; or a DNA sequence comprising sequences of codons which, on expression, code for a polypeptide displaying similar immunological or biological activity to a polypeptide coded for on expression of the codons of any of the foregoing hybrid DNA sequences and inserts characterised in that said carrier molecule causes enhancement of the immune response of a host to said immunogen, such that said enhancement is not substantially increased by the addition of an adjuvant to said complex when said complex is administered to said host, regardless of whether said complex is administered parenterally, enterally or orally and said immunogen comprises an antigen or hapten.

22. A hybrid DNA sequence according to claim 21 wherein said hybrid DNA sequence codes for at least part of TraT, OmpF or OmpA fused to an immunogen.

23. A hybrid DNA sequence according to claim 22 wherein said hybrid DNA sequence codes for at least part of TraT fused to an immunogen.

24. A hybrid DNA sequence according to claim 22 or 23, said DNA sequence coding for a TraT, OmpF or OmpA hybrid protein capable of being exported to and exposed on the surface of a host cell.

25. A fused gene comprising a hybrid DNA sequence according to any one of claims 21 to 24 fused to a portable promoter.

26. A fused gene according to claim 25 wherein the promoter is the P_L

promoter of the bacteriophage λ .

27. A recombinant DNA molecule comprising a hybrid DNA sequence or fused gene according to any one of claims 21 to 26 and vector DNA.

28. A recombinant DNA molecule according to claim 27 wherein the vector DNA is of plasmid, bacteriophage, viral or cosmid origin.

29. A recombinant DNA molecule according to claim 28 which comprises an expression control sequence operatively linked to the hybrid DNA sequence.

30. The recombinant DNA molecule pBTA371, pBTA439, pBTA449, pBTA450 or pBTA 586.

31. A process for the production of a recombinant DNA molecule according to any one of claims 27 to 30 which process comprises:

introducing into vector DNA, a hybrid DNA sequence or fused gene according to any one of claims 21 to 28.

32. A process according to claim 31 which process additionally comprises introducing an expression control sequence into the vector DNA.

33. A transformant host comprising a host cell transformed with at least one recombinant DNA molecule according to any one of claims 27 to 30.

34. A transformant host according to claim 32 wherein the host is E. coli or a Salmonella species.

35. ATCC 67331.

36. A process for the transformation of a host comprising:

introducing into a host a recombinant DNA molecule according to any one of claims 27 to 30.

37. A whole bacterial cell vaccine comprising a hybrid protein according to claim 17 exposed on the bacterial cell surface for presentation to the immune system.

38. A whole cell vaccine according to claim 37 which vaccine is a live or killed whole cell oral vaccine.

39. A vaccine comprising a hybrid protein according to claim 18 purified from the cell membrane or cellular contents.

40. A process for the manufacture of a microorganism with the genetic information for the biosynthesis of a hybrid protein comprising at least an immunogen and a carrier said carrier comprising at least part of an imp of prokaryote or eukaryote origin, such that the resulting hybrid protein is exposed on the host cell surface, which process comprises culturing a microorganism carrying the necessary genetic information.


41. A process for the production of a subunit vaccine which process comprises purifying a hybrid protein according to claim 18 from the cell membrane or cellular contents of a microorganism produced by a process


according to claim 40.


42. A process for the preparation of a complex of carrier with immunogen in a form adapted for parenteral, oral, or enteral administration to a host which process comprises:

preparing the complex and adding it to a pharmaceutically acceptable diluent.


43. A complex according to any one of claims 1 to 7 adapted for parenteral, enteral or oral administration to a host.









ORIGINAL
11 SHEETS, SHEET 4



FIGURE 3a. Plasmid Constructions

FIGURE 3a. Plasmid Constructions




FIGURE 3b. Expression of TraT and TraTvp7 fusion proteins:SDS-PAGE.




FIGURE 3b Expression of TraT and TraT-vp7
fusion proteins: Western analysis




FIGURE 3c. Cell surface labelling of E.coli

ORIGINAL
11 SHEETS, SHEET 10




FIGURE 4b Cell envelope preparations of E. coli
N4830 ± pBTA586 from uninduced (30°C)
and induced (42°C) cultures: SDS-PAGE




FIGURE 4a.

INTERNATIONAL SEARCH REPORT

International Application No PCT/AU 87/00107

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC Int. Cl. ⁴ C07K 15/04, 15/12, C07H 21/04, C12N 1/20, 15/00, C12P 19/34, 21/00, 21/02, A61K 39/385																							
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 25%; text-align: left; border-bottom: 1px solid black;">Classification System</th> <th style="text-align: left; border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="padding: 5px; vertical-align: top;">IPC</td> <td style="padding: 5px; vertical-align: top;">DERWENT WORLD PATENT INDEX: KEYWORDS: "MEMBRANE PROTEIN"</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁸</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; padding: 5px; vertical-align: top;">US</td> <td style="padding: 5px; vertical-align: top;">DERWENT US PATENT INDEX } KEYWORDS "MEMBRANE PROTEIN"</td> </tr> <tr> <td style="padding: 5px; vertical-align: top;">AU</td> <td style="padding: 5px; vertical-align: top;">CHEMICAL ABSTRACTS } IPC C07G 7/00, C07K 15/12, C12N 15/00</td> </tr> </table>			Classification System	Classification Symbols	IPC	DERWENT WORLD PATENT INDEX: KEYWORDS: "MEMBRANE PROTEIN"	US	DERWENT US PATENT INDEX } KEYWORDS "MEMBRANE PROTEIN"	AU	CHEMICAL ABSTRACTS } IPC C07G 7/00, C07K 15/12, C12N 15/00													
Classification System	Classification Symbols																						
IPC	DERWENT WORLD PATENT INDEX: KEYWORDS: "MEMBRANE PROTEIN"																						
US	DERWENT US PATENT INDEX } KEYWORDS "MEMBRANE PROTEIN"																						
AU	CHEMICAL ABSTRACTS } IPC C07G 7/00, C07K 15/12, C12N 15/00																						
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; text-align: left; border-bottom: 1px solid black;">Category ¹⁰</th> <th style="text-align: left; border-bottom: 1px solid black;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 15%; text-align: left; border-bottom: 1px solid black;">Relevant to Claim No. ¹³</th> </tr> <tr> <td style="padding: 5px; vertical-align: top;">X</td> <td style="padding: 5px; vertical-align: top;">US,A, 4459286 (HILLEMANN et al) 10 July 1984 (10.07.84)</td> <td style="padding: 5px; vertical-align: top;">(1-2,41,42)</td> </tr> <tr> <td style="padding: 5px; vertical-align: top;">X,Y</td> <td style="padding: 5px; vertical-align: top;">EP,A, 109688 (THE WELLCOME FOUNDATION LIMITED) 30 May 1984 (30.05.84) See claim 1 and pages 3-4</td> <td style="padding: 5px; vertical-align: top;">(1-2,41,42)</td> </tr> <tr> <td style="padding: 5px; vertical-align: top;">X,Y</td> <td style="padding: 5px; vertical-align: top;">EP,A, 145359 (THE WELLCOME FOUNDATION LIMITED) 19 June 1985 (19.06.85) See page 3, claim 1</td> <td style="padding: 5px; vertical-align: top;">(1-2,41,42)</td> </tr> <tr> <td style="padding: 5px; vertical-align: top;">X</td> <td style="padding: 5px; vertical-align: top;">Derwent Abstract Accession No. 86-176377/27 class B04, US,A, 6777068 (US SECRETARY OF THE ARMY) 1 April 1986 (01.04. 86)</td> <td style="padding: 5px; vertical-align: top;">(1-2,41,42)</td> </tr> <tr> <td style="padding: 5px; vertical-align: top;">X</td> <td style="padding: 5px; vertical-align: top;">EP,A, 55942 (THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK) 14 July 1982 (14.07.82) See claim 1 and figure 4</td> <td style="padding: 5px; vertical-align: top;">(20,26,33)</td> </tr> <tr> <td style="padding: 5px; vertical-align: top;">X</td> <td style="padding: 5px; vertical-align: top;">EP,A, 94797 (THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK) 23 November 1983 (23.11.83) See claim 1</td> <td style="padding: 5px; vertical-align: top;">(20,26,33)</td> </tr> </table>			Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	US,A, 4459286 (HILLEMANN et al) 10 July 1984 (10.07.84)	(1-2,41,42)	X,Y	EP,A, 109688 (THE WELLCOME FOUNDATION LIMITED) 30 May 1984 (30.05.84) See claim 1 and pages 3-4	(1-2,41,42)	X,Y	EP,A, 145359 (THE WELLCOME FOUNDATION LIMITED) 19 June 1985 (19.06.85) See page 3, claim 1	(1-2,41,42)	X	Derwent Abstract Accession No. 86-176377/27 class B04, US,A, 6777068 (US SECRETARY OF THE ARMY) 1 April 1986 (01.04. 86)	(1-2,41,42)	X	EP,A, 55942 (THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK) 14 July 1982 (14.07.82) See claim 1 and figure 4	(20,26,33)	X	EP,A, 94797 (THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK) 23 November 1983 (23.11.83) See claim 1	(20,26,33)
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³																					
X	US,A, 4459286 (HILLEMANN et al) 10 July 1984 (10.07.84)	(1-2,41,42)																					
X,Y	EP,A, 109688 (THE WELLCOME FOUNDATION LIMITED) 30 May 1984 (30.05.84) See claim 1 and pages 3-4	(1-2,41,42)																					
X,Y	EP,A, 145359 (THE WELLCOME FOUNDATION LIMITED) 19 June 1985 (19.06.85) See page 3, claim 1	(1-2,41,42)																					
X	Derwent Abstract Accession No. 86-176377/27 class B04, US,A, 6777068 (US SECRETARY OF THE ARMY) 1 April 1986 (01.04. 86)	(1-2,41,42)																					
X	EP,A, 55942 (THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK) 14 July 1982 (14.07.82) See claim 1 and figure 4	(20,26,33)																					
X	EP,A, 94797 (THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK) 23 November 1983 (23.11.83) See claim 1	(20,26,33)																					
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁴ Special categories of cited documents: ¹⁵</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"G" document member of the same patent family</p> </div> </div>																							
IV. CERTIFICATE ¹⁶ <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 5px; vertical-align: top;"> Date of the Actual Completion of the International Search 23 July 1987 (23.07.87) </td> <td style="width: 50%; padding: 5px; vertical-align: top;"> Date of Mailing of this International Search Report (28.07.87) 28 JULY 1987 </td> </tr> <tr> <td style="padding: 5px; vertical-align: top;"> International Searching Authority Australian Patent Office </td> <td style="padding: 5px; vertical-align: top;"> Signature of Authorized Officer <div style="text-align: center;"> J.H. CHAN </div> </td> </tr> </table>			Date of the Actual Completion of the International Search 23 July 1987 (23.07.87)	Date of Mailing of this International Search Report (28.07.87) 28 JULY 1987	International Searching Authority Australian Patent Office	Signature of Authorized Officer <div style="text-align: center;"> J.H. CHAN </div>																	
Date of the Actual Completion of the International Search 23 July 1987 (23.07.87)	Date of Mailing of this International Search Report (28.07.87) 28 JULY 1987																						
International Searching Authority Australian Patent Office	Signature of Authorized Officer <div style="text-align: center;"> J.H. CHAN </div>																						

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claim numbers 20 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically: The terms "a DNA sequence related by mutation, including single or multiple base substitutions, deletions, insertions and inversions to said first DNA sequence; or a DNA sequence comprising sequences of codons which, on expression, code for a polypeptide displaying similar immunological or biological activity to a polypeptide coded for an expression of the codons of any of the foregoing hybrid DNA sequences and inserts." are indeterminate in scope.

3. ☐ Claim numbers because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
☐ No protest accompanied the payment of additional search fees.

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON
INTERNATIONAL APPLICATION NO. PCT/AU 87/00107

Patent Document
Cited in Search
Report

Patent Family Members

US	4459286	AU	23799/84	DK	404/84	EP	117783
		ES	529264	FI	840242	IL	70727
		JP	59141523	NO	840341	PT	77977

EP	109688	JP	59176214
----	--------	----	----------

EP	145359	JP	61186328
----	--------	----	----------

EP	55942	DK	5823/81	GB	2091269	IL	64783
		JP	57140800	US	4624926	US	4666836
		CA	1207684	IL	64783		

EP	94797	AU	14506/83	CA	1205764	DD	210466
		DK	2150/83	GB	2120255	IL	68627
		JP	59051793				

END OF ANNEX